MAXCYTE, INC.
No SEC Form 4 filings for $MXCT in the last 30 days.
See all $MXCT insider activity →MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reitera
MaxCyte (MXCT) said it signed a multi-platform technology license partnership with Genentech, a Roche Group member (RHHBY), to support next-generation cell therapy programs. Genentech will access MaxCyte’s ExPERT GTx platform and other technologies across research, clinical development, and manufacturing workflows. MaxCyte’s stock closed at $1.23, up 5.13% on the day.
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of e
Over the past 7 days, alphai's AI scored 1 news story mentioning MXCT (MAXCYTE, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MXCT coverage spans financial news, earnings and mergers & acquisitions.
The 8-K combines an earnings-style datapoint (Q2 results and margins), forward guidance, and a new large pharma licensing partnership, which can re-rate near-term revenue mix and longer-term royalty visibility.
The deal is a new commercial/licensing catalyst that can support future revenue visibility, but the article provides no financial terms or timeline.
This is a routine corporate governance disclosure with no new operating or financial guidance.
MaxCyte's Q1 2026 revenue declined slightly, but expenses decreased significantly, leading to a narrower net loss. The company's strong gross margin and cash position suggest financial stability.
MaxCyte exceeded Q1 2026 forecasts with strong revenue growth, especially in SPL program-related revenue, leading to a stock price increase. The company's reaffirmed guidance and share repurchase indicate confidence in future performance.
alphai scores every news story that mentions MXCT with an AI model for sentiment and relevance, and aggregates insider trades from MAXCYTE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reitera
6 min readMaxCyte (MXCT) said it signed a multi-platform technology license partnership with Genentech, a Roche Group member (RHHBY), to support next-generation cell therapy programs. Genentech will access MaxCyte’s ExPERT GTx platform and other technologies across research, clinical development, and manufacturing workflows. MaxCyte’s stock closed at $1.23, up 5.13% on the day.
3 min readMAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of e
2 min readMaxCyte (NASDAQ: MXCT) reported its Q1 2026 financial results, showing a decrease in revenue to $9.7 million from $10.4 million in the prior year, though the net loss narrowed significantly to $4.8 million from $10.3 million due to reduced operating expenses. The decline in revenue was attributed to weaker core product and license sales, partially offset by an increase in Strategic Platform License milestones and royalties. The company maintained a high gross margin of 84% and expects its existing cash and investments to fund operations for at least the next 12 months.
3 min readMaxCyte (MXCT) exceeded first-quarter 2026 forecasts, reporting an EPS of -$0.04 against an expected -$0.08, and revenue of $9.7 million, significantly higher than the $7.3 million forecast. The company's stock rose 2.2% in aftermarket trading, driven by strong SPL program-related revenue growth despite an overall 7% decrease in total revenue year-over-year. MaxCyte reiterated its full-year 2026 guidance, expecting total revenue between $30 million and $32 million, and announced a $10 million share repurchase program, underscoring confidence in its long-term value and strategic investments.
2 min readMaxCyte (MXCT) CEO Masoud Maher was granted an equity compensation package including 600,000 stock options and 300,000 restricted stock units (RSUs). The stock options have an exercise price of $0.684 per share and expire in 2036, with vesting tied to continued service. The RSUs also vest over several years, contingent on his employment with the company.
2 min readMaxCyte will now host its earnings conference call on November ...
4 min readROCKVILLE, Md., Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ:MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will ...
3 min readROCKVILLE, Md., Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it ...
2 min readROCKVILLE, Md., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc. ( NASDAQ:MXCT ) , a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of ...
3 min read
